首页> 美国卫生研究院文献>Journal of Clinical and Translational Science >3533 Delayed Administration Of Angiotensin Receptor (AT2R) Agonist C21 Downregulates Diabetes Induced Pro-Inflammatory Microglia Activation To Improve Cognitive Functional Recovery Post Stroke: Therapeutic Indications For The Treatment Of Vascular Cognitive
【2h】

3533 Delayed Administration Of Angiotensin Receptor (AT2R) Agonist C21 Downregulates Diabetes Induced Pro-Inflammatory Microglia Activation To Improve Cognitive Functional Recovery Post Stroke: Therapeutic Indications For The Treatment Of Vascular Cognitive

机译:3533血管紧张素受体(AT2R)激动剂C21的延迟给药下调糖尿病诱导的促炎性小胶质细胞活化以改善卒中后的认知和功能恢复:用于治疗血管性认知的治疗指征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVES/SPECIFIC AIMS: The study aim was to 1) elucidate mechanisms contributing to the evolution of PSCI using a clinically relevant model of diabetes, a major risk factor for stroke and cognitive impairment, and 2) develop angiotensin type 2 receptor (AT2R) agonism as a therapeutic target. METHODS/STUDY POPULATION: Diabetes was induced in male Wistar rats by a HFD & low dose streptozotocin combination. At 12-14 weeks of age a total of 69 control & diabetic rats were subjected to 1 hr middle cerebral artery occlusion (MCAO) or Sham surgery. 3 days post-MCAO, rats that met the pre-set inclusion criteria were administered C21 or saline in drinking water at a dose of 0.12 mg/kg/day Adhesive removal task (ART) & 2-trial Ymaze were utilized to test sensorimotor & cognitive function at baseline as well as 1, 2, 4 and 8 weeks post-stroke. At week 8 post-stroke cell suspensions from freshly harvested brains were analyzed by flow cytometry utilizing antibodies against cell surface markers for M1 (CD11b+/CD45 low/ CD86+/TNFa+), M2 (CD11b+/CD45 low/ CD206+/IL-10+), and residential microglia (CD11b+/CD45+/ TMEM119+). RESULTS/ANTICIPATED RESULTS: Control rats progressively recovered from stroke-induced functional deficits by week 8, while diabetics still remained impaired (P< 0.05). 8 weeks post-MCAO only diabetic rats exhibited a decline in sensorimotor (P< 0.05) and cognitive function (P< 0.05) compared to Shams. Delayed administration of C21 on D2 post-stroke halted the decline and improved sensorimotor (P< 0.05) and cognitive function (P< 0.01). Flow cytometric analyses indicate that 8 post-stroke vehicle diabetics had an elevated M1/M2 ratio within the ipsilateral prefrontal cortex and hippocampus (P< 0.01, 0.01). They also had a larger percentage of non-residential microglia/macrophages, indicative of compromised blood brain barrier (BBB) integrity. Treatment with C21 significantly lowered the M1/M2 ratio (P< 0.05) and improved the BBB integrity. DISCUSSION/SIGNIFICANCE OF IMPACT: Taken together this study suggests that the use of comorbid disease models such as diabetes, may allow for more translational evaluations of PSCI. Higher translational relevance may also lead to a higher number of successful clinical trials and more FDA approved stroke therapies. It also suggests that C21 may serve as a potential therapeutic to modulate the development of PSCI.
机译:目标/特定目的:研究目的是:1)使用临床相关的糖尿病模型,中风和认知障碍的主要危险因素,阐明促成PSCI进化的机制,以及2)形成2型血管紧张素受体(AT2R)激动作用作为治疗目标。方法/研究人群:HFD和低剂量链脲佐菌素组合可诱发雄性Wistar大鼠糖尿病。在12-14周龄时,总共对69只对照组和糖尿病大鼠进行了1小时的大脑中动脉闭塞(MCAO)或Sham手术。 MCAO后3天,对符合预设纳入标准的大鼠以0.12 mg / kg / day的剂量在饮用水中施用C21或生理盐水,并采用去除胶粘剂任务(ART)和2次试验性迷宫来测试感觉运动和基线以及中风后1、2、4和8周的认知功能。在第8周时,使用针对M1(CD11b + / CD45 low / CD86 + / TNFa +),M2(CD11b + / CD45 low / CD206 + / IL-10 +)细胞表面标志物的抗体,通过流式细胞术分析来自新近收获的大脑的中风后细胞悬液,以及住宅小胶质细胞(CD11b + / CD45 + / TMEM119 +)。结果/预期结果:对照组大鼠在第8周时逐渐从中风诱发的功能障碍中恢复,而糖尿病患者仍然受损(P <0.05)。与Shams相比,仅在MCAO后8周,仅糖尿病大鼠的感觉运动(P <0.05)和认知功能(P <0.05)下降。中风后D2延迟给予C21可以阻止这种下降,并改善感觉运动(P <0.05)和认知功能(P <0.01)。流式细胞仪分析表明,8例中风后糖尿病患者的同侧前额叶皮层和海马中的M1 / M2比升高(P <0.01,0.01)。他们还具有较大比例的非居住区小胶质细胞/巨噬细胞,表明血脑屏障(BBB)完整性受损。 C21处理可显着降低M1 / M2比率(P <0.05)并改善BBB完整性。讨论的意义/意义:这项研究综合表明,使用合并症模型(例如糖尿病)可能允许对PSCI进行更多的翻译评估。更高的翻译相关性也可能导致更多的成功临床试验和更多的FDA批准的中风疗法。这也表明,C21可能作为调节PSCI发育的潜在疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号